A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Breakpoint based on release 3 sequence coordinate from Thibault et al., 2004, Supplementary Table 3 (FBrf0174228), converted to release 5 coordinate.
Breakpoint from FlyBase's release 5 sequence location of progenitor insertion.
Inferred to overlap with: Df(3R)WIN11.
Inferred to overlap with: Df(3R)BSC193.
Lethal in combination with TM6B-Tb.
The presence of P+PBac{XP5.WH5}BSC744 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of P{XP}d03025 to be Release 3 genomic coordinate 2231048 on chromosome arm 3R. This corresponds to 83E6 on the Release 3 and Release 5 genome maps. The predicted position of PBac{WH}CG17917f06982 on the Release 5 map is 83E4. Consequently, the cytological breakpoints of Df(3R)BSC744 are predicted to be 83E4;83E6.